TABLE 2.
Demographic, clinical, and neuropathologic characteristics of the ADNI participants without neuropathology confirmation.
| Characteristics | Cognitively unimpaired | MCI | Dementia |
|---|---|---|---|
| N | 298 | 376 | 198 |
| Age at MRI, years (SD) | 73.4 (6.7) | 72.2 (7.6) | 74.2 (7.9) |
| Female, n (%) | 166 (56) | 178 (44) | 74 (39) |
| MMSE at MRI, mean (SD) | 28.9 (1.4) | 27.2 (2.9) | 23.0 (3.8) |
| Clinical dementia rating at MRI, mean (SD) | 0.1 (0.2) | 0.5 (0.2) | 0.9 (0.6) |
| At least one copy of APOE ε4 allele, n (%) | 86 (29) | 175 (44) | 131 (70) |
| At least one copy of APOE ε2 allele, n (%) | 40 (14) | 33 (8) | 11 (6) |
| White matter hyperintensity lesion burden (% ICV), mean (SD) | 0.46 (0.76) | 0.62 (0.80) | 0.62 (0.70) |
| Modified Hachinski score*, n (%) | |||
| 0 | 158 (53) | 166 (44) | 97 (49) |
| 1 | 126 (42) | 186 (49) | 91 (46) |
| 2 | 10 (3) | 10 (3) | 6 (3) |
| 3 | 4 (1) | 11 (3) | 3 (2) |
| 4 | 0 (0) | 3 (1) | 1 (< 1) |
| Biomarker evidence for AD pathology | |||
| Aβ PET SUVR, mean (SD) | 1.1 (0.2) | 1.2 (0.2) | 1.4 (0.2) |
| PET Aβ+, n (%) | 100 (34) | 210 (52) | 166 (88) |
| CSF p‐tau181, mean (SD) | 21.5 (9.2) | 25.8 (14.1) | 36.4 (15.5) |
| CSF p‐tau181+, n (%) | 91 (31) | 169 (42) | 156 (83) |